On October 25, 2022 Salubris Pharmaceuticals reported that it signed a co-development agreement with Anlong Bio. The two drugmakers will collaborate in the development of small nucleic acid drugs to treat hypertension (Press release, Salubris Pharmaceuticals, OCT 25, 2022, View Source [SID1234622550]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Anlong will be responsible for the early development using its proprietary ANOG small nucleic acid drug technology platform, while Salubris will oversee later development, clinical trials and marketing of the product.

Salubris will have exclusive rights to develop and commercialize the drug worldwide, and both companies will share the future market and commercial benefits.

Salubris was founded in 1998 and focuses on the cardio-cerebrovascular field. It also explores innovative drugs for the treatment of hypoglycemia, tumors, orthopedics, nephropathy and anti-infection. This collaboration marks Salubris’ first entry into the emerging field of nucleic acid drugs.